LYMPHANGIOSIS CARCINOMATOSA

This adverse event was reported 1042 times

These drugs are most commonly taken by patients reporting LYMPHANGIOSIS CARCINOMATOSA:

# Drug Count
0 CARBOPLATIN 104
1 PACLITAXEL 82
2 TRASTUZUMAB 81
3 PEMBROLIZUMAB 79
4 BEVACIZUMAB 77
5 CAPECITABINE 77
6 EVEROLIMUS 74
7 PACLITAXEL (AIBUMIN-BOUND) 74
8 NIVOLUMAB 73
9 LETROZOLE 70
See all common drugs associated with LYMPHANGIOSIS CARCINOMATOSA

LYMPHANGIOSIS CARCINOMATOSA is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 4% LIDOCAINE 1 0.0303
1 MATICO, SARSAPARILLA (SMILAX REGELII), THUJA OCCIDENTALIS, UNCARIA TOMENTOSA, PHYLLANTHUS NIRURI, POLYGONUM CUSPIDATUM 1 0.0139
2 ISOTONIC SODIUM CHLORIDE 1 0.0133
3 ZONGERTINIB 1 0.0060
4 GEFITINIB 43 0.0048
5 AFATINIB 27 0.0041
6 DACOMITINIB 3 0.0040
7 VINORELBINE 23 0.0033
8 NALDEMEDINE 5 0.0030
9 BELZUTIFAN 5 0.0028
See all drugs enriched for association with LYMPHANGIOSIS CARCINOMATOSA